Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MiNK Therapeutics, Inc. (INKT)

MiNK Therapeutics Q1 2026 net loss narrows to $2.7 million, or $0.57 per share

Positive Impact 3 of 5 earnings Written later

MiNK Therapeutics reported first quarter 2026 results on May 15, 2026. The net loss was about $2.7 million, or $0.57 per share, compared with about $2.8 million, or $0.70 per share, in the same period of 2025. Cash and cash equivalents fell to about $9.5 million from about $13.4 million at December 31, 2025, after the company repaid about $5.2 million on the Agenus convertible note.

Key points

  • Net loss of about $2.7 million, or $0.57 per share, for the quarter ended March 31, 2026, versus about $2.8 million, or $0.70 per share, a year earlier
  • Cash and cash equivalents of about $9.5 million at March 31, 2026, versus about $13.4 million at December 31, 2025
  • Repaid about $5.2 million on the Agenus convertible note; raised about $3.0 million through its at-the-market sales agreement in the quarter
  • Randomized Phase 2 trial of agenT-797 initiated, with preliminary data expected in the second half of 2026; ATS presentation scheduled for May 20, 2026

The filing

CompanyMiNK Therapeutics, Inc. (INKT)
Form8-K, current report
Filed with the SECMay 15, 2026, 8:03 AM ET
Accession number0001193125-26-225369

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.